Logo do repositório
 
Publicação

Is achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: insights from the EUREkA cohort

2026-06-01Artigo de investigação Acesso aberto
Ver registo simples
dc.contributor.authorCaronna, Edoardo
dc.contributor.authorMas-de-les-Valls, Rut
dc.contributor.authorEgeo, Gabriella
dc.contributor.authorVázquez, Manuel Millán
dc.contributor.authorCastellanos, Candela Nieves
dc.contributor.authorMembrilla, Javier A.
dc.contributor.authorVaghi, Gloria
dc.contributor.authorRodríguez-Montolio, Joana
dc.contributor.authorFabra, Neus Fabregat
dc.contributor.authorCaballero, Francisco Sánchez
dc.contributor.authorJaimes, Alex
dc.contributor.authorMuñoz-Vendrell, Albert
dc.contributor.authorOliveira, Renato
dc.contributor.authorGárate, Gabriel
dc.contributor.authorOsorio, Yesica González
dc.contributor.authorGuisado-Alonso, Daniel
dc.contributor.authorOrnello, Raffaele
dc.contributor.authorThunstedt, Cem
dc.contributor.authorFernández-Lázaro, Iris
dc.contributor.authorSánchez-Soblechero, Antonio
dc.contributor.authorHusøy, Andreas Kattem
dc.contributor.authorVicente, Beatriz Nunes
dc.contributor.authorBasedau, Hauke
dc.contributor.authorPérez, Nuria Pilar Riesco
dc.contributor.authorPina, Belen Flores
dc.contributor.authorFernandes, Catarina
dc.contributor.authorAndrés-López, Alberto
dc.contributor.authorMartins-Silva, Elisa
dc.contributor.authorBudrewicz, Sławomir
dc.contributor.authorArlanzón, Pablo Ros
dc.contributor.authorCaetano, André
dc.contributor.authorGallardo, Victor José
dc.contributor.authorGómez-Dabó, Laura
dc.contributor.authorTorres-Ferrús, Marta
dc.contributor.authorAlpuente, Alicia
dc.contributor.authorTorelli, Paola
dc.contributor.authorAurilia, Cinzia
dc.contributor.authorZapata, Silvana
dc.contributor.authorPérez, Raquel Lamas
dc.contributor.authorCastrillo, Maria José Ruiz
dc.contributor.authorIcco, Roberto De
dc.contributor.authorSances, Grazia
dc.contributor.authorBroadhurst, Sarah
dc.contributor.authorOng, Hui Ching
dc.contributor.authorWinstanley, Jed
dc.contributor.authorAranceta, Sonsoles
dc.contributor.authorZubizarreta, Izaro Kortazar
dc.contributor.authorMarques, Inês
dc.contributor.authorCabral, Gonçalo
dc.contributor.authorGil-Gouveia, Raquel
dc.date.accessioned2026-07-09T15:14:34Z
dc.date.available2026-07-09T15:14:34Z
dc.date.issued2026-06-01
dc.description.abstractBackground: The International Headache Society has proposed new treatment goals for migraine prevention in real world, as a way to set higher standards of care. This study provides the first assessment of the proportion of individuals achieving them after 6 months of migraine-specific treatment with anti-CGRP monoclonal antibodies (MAbs). Methods: This was a prospective, real-world, European multicenter study, including adults with migraine treated with anti-CGRP MAbs (EUREkA cohort). We assessed the proportions of individuals in each treatment goal category–migraine freedom (no monthly migraine days [MMD]); optimal control (< 4 MMD), modest control (4–6 MMD); insufficient control (>6 MMD)–after 6 months of treatment. We also assessed the proportion of individuals with ≥50% reduction in MMD in the insufficient control group. Results: Of the 5818 individuals in the EUREkA cohort, 4963 had 6 months data. Of these, 82.3% (4086/4963) were females and the median age was 48.0 [40.0–55.0] years. At baseline, the median monthly headache days [MHD] and MMD were 20.0 [13.3–28.0] and 15.0 [10.0–20.0], respectively. All participants were classified as having insufficient headache control (>6 MMD) at baseline. At month 6, 6.9% (342/4963) had migraine freedom, 22.9% (1137/4963) optimal control, 24.6% (1223/4963) modest control and 45.6% (2261/4963) insufficient control. In the insufficient control group, 27.1% (613/2261) had ≥50% reduction in MMD. Conclusions: High standards of care, defined as optimal disease control or even migraine freedom, are achieved in real-world settings with anti-CGRP MAbs in approximately 30% of individuals with a high migraine burden. These findings highlight the need to expand global access to these treatments. Future studies should explore whether initiating migraine-specific preventive treatments earlier could further reduce residual migraine days in responders, enabling a larger proportion of patients to achieve optimal disease control.eng
dc.identifier.doi10.1177/03331024261440370
dc.identifier.eid105043105695
dc.identifier.otherf34c9fb3-b80a-4c9f-890d-41e70f2fb3ff
dc.identifier.pmid42318706
dc.identifier.urihttp://hdl.handle.net/10400.14/58608
dc.language.isoeng
dc.peerreviewedyes
dc.publisherSAGE Publications Ltd
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subjectCGRPeng
dc.subjectInsufficient controleng
dc.subjectMigraineeng
dc.subjectMonoclonal antibodieseng
dc.subjectOptimal controleng
dc.subjectSstandard of careeng
dc.titleIs achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: insights from the EUREkA cohort
dc.typeresearch article
dspace.entity.typePublication
oaire.citation.issue6
oaire.citation.volume46
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
155350292.pdf
Tamanho:
5.08 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

CIIS - Contribuições em Revistas Científicas / Contribution to Journals